Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Three Amigos Stock Thread -- Ignore unavailable to you. Want to Upgrade?

To: Sal D who wrote (7192)	7/26/1998 8:26:00 PM
From: Sal D	Respond to of 29382

Some notes, Osteotech, Inc. (OSTE) reported a 73% increase in second-quarter profits on the strength of growing sales in its bone transplant products. Net income of $2.43 million, or 26 cents a diluted share, as compared to $1.40 million, or 17 cents a diluted share over the same period last year. Osteoteck process bones from organ donors and then Surgeons use those bones for transplants. They also make a demineralized bone product called Grafton, which is essentially pure bone protein without the minerals that make bones hard. Physicians use Grafton during transplants to promote bone growth. Roberts Pharmaceutical Corp. (RPC) had earnings that almost doubled analysts expectations but the stock price still fell on Tuesday as did most major pharmaceutical companies. Roberts stock declined $2.50 per share that day after the company announced earnings of $4.7 million, or 15 cents per share, on revenue of $44.4 million for the three months ending June 30. That was above the 8 cents to 9 cents in earnings predicted by First Call, although 4 cents of the quarterly earnings came from a one time boost resulting from the sale of contract research organization. During the same period last year, Roberts earned $1.3 million, or 4 cents per share, on revenue of $30.3 million. Lucent Technologies (LU) on Tuesday announced two new contracts worth up to $3.2 billion, including a five year deal with telephone company SBC communications, Inc. The SBC agreement, valued at $2.4 billion, is Lucent's largest single contract since it spun off by AT&T. They also made inroads in there attempts to increase international sales with the announcement of two contracts with Saudi Telecommunications Co. valued at $810 million. The work will include the expansion of Saudi Arabia's GSM mobile phone network and modernization of the country's telephone network, it is one of the largest sales they have had overseas, and there largest for GSM (technology). (I wonder why Amigo Cary picked LU) AT&T Corp. (T) Thursday reported a 20% profit gain in the second quarter, slightly beating Wall Street forecasts. However, revenue increased by only 1%, dragged down by a 3.7% drop in the company's sales of long distance phone calls to consumers. This is not the first time AT&T showed erosion in its core business, as rivals such as MCI and Sprint relentlessly try and lure away the 70 million AT&T residential phone customers with competitive offers. Joe